ChiCTR-IPR-15005758
正在进行
/
/
/
2015-01-02
/
/
comorbid generalized anxiety disorder and diarrhea-predominant irritable bowel syndrome
電針灸對同時患有經常焦慮症和肚瀉型腸易激綜合症的療效研究
電針灸對同時患有經常焦慮症和肚瀉型腸易激綜合症的療效研究
電針灸對同時患有經常焦慮症和肚瀉型腸易激綜合症的療效
随机平行对照
治疗新技术
block randomisation
Randomized
Health and Medical Research Fund
/
74;0
/
2015-01-15
1990-01-01
/
1. Rome III criteria for irritable bowel syndrome- diarrheal subtype: (1) Current (weekly) symptoms of type and severity: i. Abdominal pain intensity: weekly average of worst daily (in the past 24 hours) abdominal pain score of at least 1 on 0-4 5-point Likert scale, AND ii. Stool consistency: at least one stool with a consistency of Type 6 or Type 7 Bristol Stool Score in at least 25% of the time. (2) Normal colonic evaluation (colonoscopy or barium enema) within the past 5 years. 2. DSM-5 Criteria for Generalized Anxiety Disorder with GAD7 score 10 or above; 3. Age >18; 4. Provision of written consent.;
请登录查看1. Functional dyspepsia (Rome III definition) and/or Gastro-esophageal reflux disease (Montreal definition) as dominant syndrome; 2. Previous gastrointestinal surgery (except appendicectomy and cholecystectomy); 3. History of organic disease of the gastrointestinal tract, such as colorectal cancer, advanced colonic polyp, celiac disease, inflammatory bowel disease, previous gastrointestinal surgery or systemic diseases that may cause diarrhea; 4. Pregnancy, lactation or not under proper contraception; 5. Concomitant use of anti-diarrheal drugs; 6. History of drug abuse or regular alcohol use in recent 6 months; 7. Active suicidal thoughts or history of violence or suicide attempts; 8. Currently suffering from depression of at least moderate severity (PHQ-9 15 or above); 9. History of severe mental illness, such as psychosis, bipolar disorder, or organic brain syndrome that may limit the response of anxiety and somatic symptoms to electroacupuncture. 10. History of psychotropic drug use or treatment in recent month xi) Currently receiving psychological treatment.;
请登录查看Department of Medicine and Therapeutics,The Chinese University of Hong Kong
/
Department of Medicine and Therapeutics,The Chinese University of Hong Kong的其他临床试验
Department of Medicine and Therapeutics,The Chinese University of Hong Kong的其他临床试验
最新临床资讯
-
Nat Rev Clin Oncol|AI赋能肿瘤临床试验:从流程优化到证据生成的全景透视
智药邦2026-08-12
-
康臣药业1类新药糖肾方“芪箭颗粒”获NMPA临床研究许可
康臣药业2026-08-12
-
璎黎药业2026-08-12
-
幂方健康基金2026-08-12
-
细胞与基因治疗领域2026-08-12
-
云南白药2026-08-12
-
细胞治疗前沿2026-08-12
-
广州达博生物制品有限公司2026-08-12
-
医药笔记2026-08-12
-
医药笔记2026-08-12
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 27
-
摩熵咨询 20 5
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构:国家医保局 2026-07-31
-
颁布机构:国家药品审评中心(CDE) 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 38
-
摩熵咨询 34 18
-
颁布机构:国家市场监督管理总局 2026-08-10
-
颁布机构:国家市场监督管理总局 2026-05-29
-
颁布机构:国家市场监督管理总局 2026-05-29
